Get the Stockscreener App
2.64
6.71%
-0.19
After Hours:
2.78
0.14
+5.30%
iBio Inc stock is traded at $2.64, with a volume of 1.59M.
It is down -6.71% in the last 24 hours and up +22.79% over the past month.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
See More
Previous Close:
$2.83
Open:
$2.79
24h Volume:
1.59M
Relative Volume:
0.29
Market Cap:
$91.20M
Revenue:
$2.05M
Net Income/Loss:
$-23.15M
P/E Ratio:
-0.3981
EPS:
-6.6319
Net Cash Flow:
$-16.93M
1W Performance:
-14.01%
1M Performance:
+22.79%
6M Performance:
+216.17%
1Y Performance:
-58.29%
1-Day Range:
$2.50
$2.83
1-Week Range:
$2.405
$3.12
52-Week Range:
$0.5562
$6.40
iBio Inc Stock (IBIO) Company Profile
Name
iBio Inc
Sector
Industry
Phone
302-355-0650
Address
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
2.64 | 97.76M | 2.05M | -23.15M | -16.93M | -6.6319 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Oppenheimer | Outperform |
| Oct-17-25 | Initiated | Leerink Partners | Outperform |
| May-28-24 | Initiated | Chardan Capital Markets | Buy |
| Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
| Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-20 | Initiated | Alliance Global Partners | Buy |
View All
iBio Inc Stock (IBIO) Latest News
iBio (NASDAQ:IBIO) Upgraded by JonesTrading to Strong-Buy Rating - MarketBeat
Jones Trading Initiates Coverage of iBio (IBIO) with Buy Recommendation - Nasdaq
JonesTrading Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $7 - 富途牛牛
iBio (IBIO) Receives New 'Buy' Rating from Jones Trading | IBIO Stock News - GuruFocus
iBio (NYSE:IBIO) Now Covered by Analysts at JonesTrading - MarketBeat
Jones Trading initiates iBio stock with buy rating on obesity platform - Investing.com Australia
Jones Trading initiates iBio stock with buy rating on obesity platform By Investing.com - Investing.com South Africa
Ibio SEC Filings - Stock Titan
Revenue per share of iBio, Inc. – MUN:0JV0 - TradingView
IBio enters open market sale agreement with Jefferies - marketscreener.com
IBio Files $200 Million Mixed Shelf Offering - marketscreener.com
iBio Launches Up to $100 Million ATM Program With Jefferies to Bolster Liquidity - TradingView
iBio (NYSE: IBIO) launches $100M at-the-market stock offering with Jefferies - Stock Titan
IBio Inc files for mixed shelf of up to $200 million - marketscreener.com
iBio Inc Files For Mixed Shelf Of Upto $200 Million - TradingView
Ken Johnson - Crain's Chicago Business
IBIO: Pipeline advances in obesity and cardiovascular drugs with strong financial backing and near-term data - TradingView
IBIO: Advancing next-gen obesity therapies with strong financials and key data readouts ahead - TradingView
Growth Report: Will iBio Inc benefit from green energy policiesMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
LifeSci Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
Aug Selloffs: Is Beazer Homes USA Inc forming a breakout patternTrade Entry Report & Long-Term Growth Portfolio Plans - baoquankhu1.vn
iBio (NYSEMKT:IBIO) Stock Price Up 2.9%Should You Buy? - MarketBeat
How do insiders feel about iBio Inc.Rate Cut & Step-by-Step Swing Trade Plans - mfd.ru
iBio to Participate in Upcoming Investor Conferences - The Manila Times
iBio leaders join fireside chats at Oppenheimer and Leerink healthcare events - Stock Titan
Critical Review: iBio (NYSE:IBIO) versus Vaxxinity (NASDAQ:VAXX) - Defense World
IBio, Inc. (IBIO) Stock: Price Predictions & Analysis - thedetroitbureau.com
ADAR1 discloses 4.4% iBio (IBIO) ownership in updated 13G filing - Stock Titan
Brookline Cap M Weighs in on iBio's Q3 Earnings (NYSE:IBIO) - MarketBeat
IBIO PE Ratio & Valuation, Is IBIO Overvalued - Intellectia AI
iBio (NASDAQ:IBIO) Rating Lowered to Sell at Wall Street Zen - MarketBeat
IBIO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
IBIO Should I Buy - Intellectia AI
Stock Recap: Will iBio Inc outperform its industry peersJuly 2025 Snapshot & Accurate Buy Signal Notifications - baoquankhu1.vn
IBIO: Chardan Capital Maintains 'Buy' Rating with Steady Price T - GuruFocus
iBio's (IBIO) Buy Rating Reiterated at Chardan Capital - MarketBeat
Can iBio Inc. stock attract ESG capital inflows2025 Fundamental Recap & Low Risk Entry Point Guides - mfd.ru
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update - The Manila Times
IBIO Inc (NASDAQ:IBIO) Secures $26 Million Lifeline Amid Quarterly Earnings Miss - ChartMill
iBio (IBIO) Bolsters Pipeline with $26M Financing - GuruFocus
iBio Earnings Review: Q2 Summary - Benzinga
iBio, Inc. SEC 10-Q Report - TradingView
iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - MSN
IBIO stock soars 12% pre-market after company announces $26 million private placement - MSN
Fed Watch: Will iBio Inc benefit from green energy policiesMarket Growth Summary & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
How iBio Inc. stock reacts to inflationary pressuresGold Moves & Free Expert Verified Stock Movement Alerts - mfd.ru
Forecast Cut: What is the implied volatility of Teck Resources LimitedTrade Signal Summary & Technical Confirmation Trade Alerts - baoquankhu1.vn
IBIO Stockholders Sell Shares Without Company Receiving Proceeds - GuruFocus
iBio (NASDAQ:IBIO) Stock Price Down 3.6%Here's Why - MarketBeat
What is the PEG ratio of iBio Inc.2025 EndofYear Setup & Growth Focused Investment Plans - mfd.ru
ImmunityBio Stock Rises 25.3% to $6.92 - intellectia.ai
iBio Inc Stock (IBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):